NCT06502691
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
At risk: Primary completion moved 12 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 31, 2027 to Dec 31, 2028 Show 5 more changesShow less
- Eligibility criteria expanded, about 16 words
- Study completion pushed from Dec 31, 2030 to Dec 31, 2031
- Secondary endpoints: details revised at 1 of 1 entry
- Study description revised
- Site details revised
- Minor Start date changed from estimate of Mar 1, 2026 to Feb 26, 2026v13
- Minor Start date: Feb 1, 2026 to Mar 1, 2026v12
- Notable Start date: Jan 1, 2026 to Feb 1, 2026v11
- Notable Start date: Nov 22, 2025 to Jan 1, 2026v10
Show 7 earlier versionsHide 7 earlier versions
- Notable Primary completion date: Dec 31, 2026 to Dec 31, 2027
- Study completion date: Dec 31, 2029 to Dec 31, 2030
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jan 1, 2026 to Nov 22, 2025
- Site details revised
- Notable Start date: Oct 1, 2025 to Jan 1, 2026v7
- Notable Start date: Jul 1, 2025 to Oct 1, 2025v6
- Notable Start date: Apr 1, 2025 to Jul 1, 2025
- Site contact updated
- Notable Start date: Jan 9, 2025 to Apr 1, 2025v4
- Notable Start date: Dec 1, 2024 to Jan 9, 2025v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
Patients receive \[18F\]FTT IV and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy and again at 12 weeks. At least 1-7 days later, patients undergo SOC FDG PET/CT and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening and during follow up.
Patients receive \[18F\]FTT IV and undergo PET scan 60-75 minutes later on day 1 of initiating SOC PARP inhibitor ± ICI therapy. At least 1-7 days later, patients undergo SOC FDG PET/CT and follow up scans at 12 weeks and 6 months. Patients may also undergo tissue biopsy during screening.
Other: Best Practice, Electronic Health Record Review, Fludeoxyglucose F-18
Procedures: Biopsy of Breast, Computed Tomography, Positron Emission Tomography
Radiation: Fluorine F 18 Fluorthanatrace
Drugs: Immune Checkpoint Inhibitor, Poly (ADP-Ribose) Polymerase Inhibitor
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States